Oncotelic Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 0.07 million. Net income was USD 0.115309 million compared to net loss of USD 0.777935 million a year ago.
For the nine months, revenue was USD 0.07 million. Net loss was USD 7.17 million compared to net income of USD 10.38 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to basic earnings per share from continuing operations of USD 0.03 a year ago. Diluted loss per share from continuing operations was USD 0.02 compared to diluted earnings per share from continuing operations of USD 0.02 a year ago.